DK2244734T3 - Fremgangsmåde til induktion af tolerance over for et allergen - Google Patents

Fremgangsmåde til induktion af tolerance over for et allergen Download PDF

Info

Publication number
DK2244734T3
DK2244734T3 DK09706855.5T DK09706855T DK2244734T3 DK 2244734 T3 DK2244734 T3 DK 2244734T3 DK 09706855 T DK09706855 T DK 09706855T DK 2244734 T3 DK2244734 T3 DK 2244734T3
Authority
DK
Denmark
Prior art keywords
allergen
probiotic
lactobacillus
allergy
food
Prior art date
Application number
DK09706855.5T
Other languages
English (en)
Inventor
Mimi Lai-Kuan Tang
Original Assignee
Murdoch Childrens Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40913317&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2244734(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from AU2008900463A external-priority patent/AU2008900463A0/en
Application filed by Murdoch Childrens Res Inst filed Critical Murdoch Childrens Res Inst
Application granted granted Critical
Publication of DK2244734T3 publication Critical patent/DK2244734T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response

Claims (15)

  1. PATENRKRAV
    1. Probiotikum og fødevareallergen til anvendelse i: (a) behandling af intolerance over for allergenet hos et individ, hvor probiotikummet og fødevareallergenet er beregnet til at blive administreret sekventielt eller simultant til individet; (b) behandling af en allergi, der er induceret af allergenet hos et individ, ved at inducere tolerance over for allergenet, hvor probiotikummet er beregnet til at blive anvendt i kombination med fødevareallergenet; eller (c) induktion af tolerance over for allergenet hos et individ, hvor probiotikummet og fødevareallergenet er beregnet til at blive administreret sekventielt eller simultant til individet; hvor probiotikummet i (a), (b) og (c) er udvalgt fra listen bestående af en art af Lactobacillus, Bifidobacterium, Escherichia, Saccharomyces, Streptococcus og Bacillus.
  2. 2. Probiotikum og fødevareallergen til anvendelse ifølge krav 1, hvor probiotikummet og fødevareallergenet er beregnet til at blive administreret i to forskellige formuleringer.
  3. 3. Probiotikum og fødevareallergen til anvendelse ifølge krav 1 eller 2, hvor probiotikummet er en art af Lactobacillus.
  4. 4. Probiotikum og fødevareallergen til anvendelse ifølge krav 3, hvor arten af Lactobacillus er udvalgt fra listen bestående af Lactobacillus acidophilus NCFM, Lactobacillus casei, Lactobacillus casei Shirota, Lactobacillus casei immunitass, Lactobacillus johnsonii, Lactococcus lactis, Lactobacillus plantarum, Lactobacillus reuteri, Lactobacillus rhamnosus, Lactobacillus salivarius og Lactobacillus helvetirus.
  5. 5. Probiotikum og fødevareallergen til anvendelse ifølge krav 4, hvor probiotikummet er Lactobacillus rhamnosus.
  6. 6. Probiotikum og fødevareallergen til anvendelse ifølge et hvilket som helst af kravene 1 til 5, hvor fødevareallergenet er et bælgplanteallergen.
  7. 7. Probiotikum og fødevareallergen til anvendelse ifølge krav 6, hvor bælgplanteallergenet er et j ordnøddeallergen.
  8. 8. Probiotikum og fødevareallergen til anvendelse ifølge et hvilket som helst af kravene 1 til 7, hvor individet er et menneske.
  9. 9. Anvendelse af et probiotikum og et fødevareallergen i fremstillingen af et medikament til at: a) behandle intolerance over for allergenet hos et individ, hvor probiotikummet og fødevareallergenet er beregnet til at blive administreret sekventielt eller simultant til individet; (b) behandle en allergi, der er induceret af allergenet hos et individ, ved at inducere tolerance over for allergenet, hvor probiotikummet er beregnet til at blive anvendt i kombination med fødevareallergenet; eller (c) inducere tolerance over for allergenet hos et individ, hvor probiotikummet og fødevareallergenet er beregnet til at blive administreret sekventielt eller simultant til individet; hvor probiotikummet i (a), (b) og (c) er udvalgt fra listen bestående af en art af Lactobacillus, Bifidobacterium, Escherichia, Saccharomyces, Streptococcus og Bacillus.
  10. 10. Anvendelse af et probiotikum og et fødevareallergen ifølge krav 9, hvor probiotikummet er en art af Lactobacillus.
  11. 11. Anvendelse af et probiotikum og et fødevareallergen ifølge krav 10, hvor arten af Lactobacillus er udvalgt fra listen bestående af Lactobacillus acidophilus NCFM, Lactobacillus casei, Lactobacillus casei Shirota, Lactobacillus casei immunitass, Lactobacillus johnsonii, Lactococcus lactis, Lactobacillus plantarum, Lactobacillus reuteri, Lactobacillus rhamnosus, Lactobacillus salivarius og Lactobacillus helvetirus.
  12. 12. Anvendelse af et probiotikum og et fødevareallergen ifølge krav 11, hvor probiotikummet er Lactobacillus rhamnosus.
  13. 13. Anvendelse af et probiotikum og et fødevareallergen ifølge et hvilket som helst af kravene 9 til 12, hvor fødevareallergenet er et bælgplanteallergen.
  14. 14. Anvendelse af et probiotikum og et fødevareallergen ifølge krav 13, hvor bælgplanteallergenet er et jordnøddeallergen.
  15. 15. Anvendelse af et probiotikum og et fødevareallergen ifølge et hvilket som helst af kravene 9 til 14, hvor individet er et menneske.
DK09706855.5T 2008-02-01 2009-01-30 Fremgangsmåde til induktion af tolerance over for et allergen DK2244734T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2008900463A AU2008900463A0 (en) 2008-02-01 A method of inducing tolerance to an allergen
PCT/AU2009/000104 WO2009094717A2 (en) 2008-02-01 2009-01-30 A method of inducing tolerance to an allergen

Publications (1)

Publication Number Publication Date
DK2244734T3 true DK2244734T3 (da) 2016-08-15

Family

ID=40913317

Family Applications (1)

Application Number Title Priority Date Filing Date
DK09706855.5T DK2244734T3 (da) 2008-02-01 2009-01-30 Fremgangsmåde til induktion af tolerance over for et allergen

Country Status (14)

Country Link
US (5) US9402896B2 (da)
EP (2) EP2244734B1 (da)
AU (1) AU2009208390B2 (da)
CY (1) CY1117948T1 (da)
DK (1) DK2244734T3 (da)
ES (2) ES2585407T3 (da)
HR (1) HRP20160945T1 (da)
HU (1) HUE029000T2 (da)
LT (1) LT2244734T (da)
NZ (1) NZ587137A (da)
PL (1) PL2244734T3 (da)
PT (1) PT2244734T (da)
SI (1) SI2244734T1 (da)
WO (1) WO2009094717A2 (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ587137A (en) * 2008-02-01 2013-02-22 Murdoch Childrens Res Inst Murdoch Childrens Res Inst A method of inducing tolerance to an allergen a method of inducing tolerance to an allergen
US10428124B2 (en) 2012-02-07 2019-10-01 La Jolla Institute For Allergy And Immunology Timothy grass allergens and methods and uses for immune response modulation
DE102012101864A1 (de) * 2012-03-06 2013-09-12 Gramme-Revit Gmbh Mittel zur Behandlung von Allergien und anderen Erkrankungen
MA41020A (fr) 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome
LT3258962T (lt) 2015-02-20 2023-02-27 The Board Of Trustees Of The Leland Stanford Junior University Mišrios alergenų kompozicijos ir jų panaudojimo būdai
US10149904B2 (en) 2015-02-20 2018-12-11 The Board Of Trusteees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US11452774B2 (en) 2015-02-20 2022-09-27 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US10143742B2 (en) 2015-02-20 2018-12-04 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US10166286B2 (en) 2015-02-20 2019-01-01 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
EP3654778A1 (en) 2017-07-18 2020-05-27 Before Brands, Inc. Methods for making mixed allergen compositions
EP3720432A4 (en) 2017-12-06 2021-08-25 Prollergy Corporation COMPOSITION AND METHOD FOR MITIGATING AN ALLERGIC REACTION
WO2020154476A1 (en) 2019-01-23 2020-07-30 Before Brands, Inc. Methods for making mixed allergen compositions
US20230049005A1 (en) * 2019-12-23 2023-02-16 Prota Therapeutics Pty Ltd Allergy treatment

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI104465B (fi) 1995-06-14 2000-02-15 Valio Oy Proteiinihydrolysaatteja allergioiden hoitamiseksi tai estämiseksi, niiden valmistus ja käyttö
AUPQ415899A0 (en) 1999-11-19 1999-12-16 Vasse Research Institute Pty Ltd Compositions for and methods of treatment of allergic diseases
AU1951001A (en) 2000-04-06 2001-09-17 Panacea Pharm Llc Microbial delivery system
US7060687B2 (en) * 2001-02-07 2006-06-13 Genmont Biotechnology Co. Live vaccines for allergy treatment
EP1364586A1 (en) 2002-05-24 2003-11-26 Nestec S.A. Probiotics and oral tolerance
KR20070089231A (ko) * 2004-12-14 2007-08-30 알크-아벨로 에이/에스 이종 단백질성 화합물을 제시하는 박테리아 세포를포함하는 약제학적 조성물
US20060233772A1 (en) 2005-04-15 2006-10-19 Udo Herz Method for preventing or treating the development of respiratory allergies
EP1723965A1 (en) * 2005-05-18 2006-11-22 Stallergenes Sa Compositions for antigen-specific induction of immuno-tolerance via oral immunization
US20090297564A1 (en) * 2005-11-04 2009-12-03 Domingo Barber Hernandez Use of a Liquid Allergy Vaccine Formulation for Oromucosal Administration
JP2009534029A (ja) * 2006-04-20 2009-09-24 ナショナル ユニバーシティ オブ シンガポール 組換え乳酸桿菌およびその使用
NZ587137A (en) * 2008-02-01 2013-02-22 Murdoch Childrens Res Inst Murdoch Childrens Res Inst A method of inducing tolerance to an allergen a method of inducing tolerance to an allergen

Also Published As

Publication number Publication date
EP2244734A2 (en) 2010-11-03
US20230107507A1 (en) 2023-04-06
SI2244734T1 (sl) 2016-11-30
NZ587137A (en) 2013-02-22
CY1117948T1 (el) 2017-05-17
US9402896B2 (en) 2016-08-02
AU2009208390B2 (en) 2014-07-17
US20110097361A1 (en) 2011-04-28
HUE029000T2 (en) 2017-02-28
ES2950396T3 (es) 2023-10-09
US20160228542A1 (en) 2016-08-11
EP3097927B1 (en) 2023-05-03
WO2009094717A3 (en) 2010-10-21
ES2585407T3 (es) 2016-10-05
HRP20160945T1 (hr) 2016-11-04
EP3097927A1 (en) 2016-11-30
EP2244734B1 (en) 2016-05-04
PT2244734T (pt) 2016-08-05
PL2244734T3 (pl) 2017-01-31
LT2244734T (lt) 2016-09-12
US20190070288A1 (en) 2019-03-07
US10071157B2 (en) 2018-09-11
WO2009094717A2 (en) 2009-08-06
US20200197515A1 (en) 2020-06-25
EP2244734A4 (en) 2012-05-23
AU2009208390A1 (en) 2009-08-06

Similar Documents

Publication Publication Date Title
DK2244734T3 (da) Fremgangsmåde til induktion af tolerance over for et allergen
Renz et al. Early life microbial exposures and allergy risks: opportunities for prevention
Al Nabhani et al. A weaning reaction to microbiota is required for resistance to immunopathologies in the adult
Nowak-Węgrzyn et al. Future therapies for food allergies
Iweala et al. Food allergy: our evolving understanding of its pathogenesis, prevention, and treatment
Jirillo et al. Anti-inflammatory and anti-allergic properties of donkey’s and goat’s milk
US9731003B2 (en) Mixed allergen compositions and methods for using the same
US10525125B2 (en) Mixed allergen compositions and methods for using the same
Isolauri et al. Role of probiotics in food hypersensitivity
Wu et al. Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells
CN103079582B (zh) 诱导调节性t细胞的增殖或积累的组合物
Smaldini et al. Orally-induced intestinal CD4+ CD25+ FoxP3+ Treg controlled undesired responses towards oral antigens and effectively dampened food allergic reactions
Du Pré et al. Tolerance to ingested deamidated gliadin in mice is maintained by splenic, type 1 regulatory T cells
US10695422B2 (en) Mixed allergen compositions and methods for using the same
Zepeda-Ortega et al. Strategies and future opportunities for the prevention, diagnosis, and management of cow milk allergy
Nowak-Węgrzyn et al. Food allergy therapy: is a cure within reach?
Scurlock et al. Oral immunotherapy for food allergy
Barten et al. Oral immunotherapy as a curative treatment for food‐allergic preschool children: Current evidence and potential underlying mechanisms
Eigenmann Pathogenesis of food allergy
Kyburz Exploiting the Intergenerational Immunomodulatory Properties of Helicobacter Pylori for the Treatment of Allergic Disorders
Feehley Commensal Bacteria and Their Metabolites Prevent Sensitization to Food Antigens
Constantinescu et al. Gastrointestinal Microbiota Impact on the Development of Food Allergy Immune Phenotype
Schwarzer Impact of Probiotic Bacteria on Allergic Sensitization in Type I Allergy Model
Hol Mucosal Immune Regulation in Early Infancy: Monitoring and Intervention
Russell Antibiotic perturbation of the intestinal microbiota in murine models of allergic airways disease